As US-based healthcare company Baxter awaits antitrust approval for its buyout of Sweden-based dialysis company Gambro, Baxter reportedly sent concessions to the European Commission to quell competition concerns over the deal within the EU, though terms of that offer were not disclosed. Reports say Baxter has yet to hear rulings on the merger within China, Australia and Ukraine, valued at $4 billion. The deal was first announced in 2012.
Featured News
LinkedIn Seeks to Block Depositions of Senior Leaders in Ongoing Antitrust Class Action
Aug 3, 2026 by
CPI
White House Finalizes Voluntary AI Cybersecurity Testing Framework
Aug 3, 2026 by
CPI
Apple Faces Russian Antitrust Investigation Tied to Domestic App Policy
Aug 3, 2026 by
CPI
Seoul Investigates Alleged Housing Price Collusion Through KakaoTalk Group
Aug 3, 2026 by
CPI
Axinn Hires Former DOJ, FTC Lawyers to Expand Antitrust Practice
Aug 3, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes